SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Compass Therapeutics, Inc. (CMPX) has a negative trailing P/E of -14.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.70%, forward earnings yield 9.49%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.08); analyst target implies upside (+105.9%).
- Forward P/E 10.5 — analysts expect a return to profitability with estimated EPS of $0.52 for FY2029.
- PEG Ratio 0.08 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -6.70% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 9.49% as earnings recover.
- Analyst consensus target $11.20 (+105.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 59/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CMPX
Valuation Multiples
P/E (TTM)-14.9
Forward P/E10.5
PEG Ratio0.08
Forward PEG0.08
P/B Ratio5.04
P/S Ratio0.00
EV/EBITDA-13.7
Per Share Data
EPS (TTM)$-0.36
Forward EPS (Est.)$0.52
Book Value / Share$1.06
Revenue / Share$0.00
FCF / Share$-0.27
Yields & Fair Value
Earnings Yield-6.70%
Forward Earnings Yield9.49%
Dividend Yield0.00%
Analyst Target$11.20 (+105.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-1.1 |
0.00 |
-0.50 |
0.00 |
- |
| 2020 |
-12.7 |
0.14 |
-3.73 |
0.00 |
- |
| 2020 |
-16.2 |
0.72 |
11.96 |
0.00 |
- |
| 2021 |
-2.4 |
-0.02 |
1.42 |
0.00 |
- |
| 2022 |
-13.5 |
0.18 |
2.91 |
0.00 |
- |
| 2023 |
-4.7 |
0.82 |
1.33 |
0.00 |
- |
| 2024 |
-4.0 |
-0.44 |
1.59 |
233.89 |
- |
| 2025 |
-12.7 |
-0.76 |
4.30 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.73 |
$0.00 |
$-38.29M |
- |
| 2019 |
$-0.67 |
$0.00 |
$-34.74M |
- |
| 2020 |
$-0.52 |
$0.00 |
$-29.5M |
- |
| 2021 |
$-1.31 |
$0.00 |
$-82.55M |
- |
| 2022 |
$-0.35 |
$0.00 |
$-36.8M |
- |
| 2023 |
$-0.33 |
$0.00 |
$-42.49M |
- |
| 2024 |
$-0.36 |
$850K |
$-49.38M |
-5808.8% |
| 2025 |
$-0.42 |
$0.00 |
$-66.49M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.40 |
$-0.62 – $-0.19 |
$1.31M |
$90.49K – $3.79M |
13 |
| 2027 |
$-0.42 |
$-0.75 – $0.40 |
$53.31M |
$3.91M – $175.87M |
11 |
| 2028 |
$-0.06 |
$-1.73 – $0.85 |
$190.32M |
$184.84M – $195.79M |
14 |
| 2029 |
$0.52 |
$-0.11 – $1.78 |
$393.67M |
$27.12M – $1.14B |
8 |
| 2030 |
$1.18 |
$-0.25 – $4.09 |
$642.27M |
$44.25M – $1.85B |
12 |
